Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
January 7th, 2019
14.3K views
This protocol provides a method to establish humanized mice (hu-NSG) via intrahepatic injection of human hematopoietic stem cells into radiation-conditioned neonatal NSG mice. The hu-NSG mouse is susceptible to HIV infection and combinatorial antiretroviral therapy (cART) and serves as a suitable pathophysiological model for HIV replication and latency investigations.
Overview
This protocol provides a method to establish humanized mice (hu-NSG) via intrahepatic injection of human hematopoietic stem cells into radiation-conditioned neonatal NSG mice. The hu-NSG mouse is susceptible to HIV infection and combinatorial antiretroviral therapy (cART), serving as a suitable model for HIV replication and latency investigations.
Key Study Components
Area of Science
- Neuroscience
- HIV/AIDS Research
- Stem Cell Biology
Background
- Humanized mice are valuable for studying human diseases.
- HIV latency and replication mechanisms are critical for developing therapies.
- The hu-NSG model allows for multi-lineage development from human stem cells.
- This technique is non-invasive and enhances research capabilities.
Purpose of Study
- To establish a reliable model for HIV research.
- To investigate the molecular mechanisms of HIV infection.
- To explore the establishment of latency reservoirs in HIV.
Methods Used
- Filtering human fetal liver tissue to obtain a single cell suspension.
- Enriching for CD34+ hematopoietic stem cells via magnetic activated cell sorting.
- Irradiating neonatal NSG mice to condition them for stem cell injection.
- Injecting human CD34+ HSCs into the liver of neonatal mice.
Main Results
- Successful establishment of hu-NSG mice that are susceptible to HIV.
- Demonstrated the feasibility of using this model for cART studies.
- Provided insights into the development of HIV latency.
- Validated the non-invasive nature of the injection technique.
Conclusions
- The hu-NSG mouse model is effective for HIV research.
- This method can advance understanding of HIV latency and infection.
- Future studies can leverage this model for therapeutic development.
Frequently Asked Questions
What are hu-NSG mice?
Hu-NSG mice are humanized mice that are susceptible to HIV infection and are used for studying HIV replication and latency.
How are human hematopoietic stem cells introduced into the mice?
They are introduced via intrahepatic injection into radiation-conditioned neonatal NSG mice.
What is the significance of using a non-invasive technique?
Non-invasive techniques minimize stress and potential harm to the animals while allowing for effective research.
What insights can be gained from this model?
The model can provide insights into the molecular mechanisms of HIV infection and the establishment of latency reservoirs.
How does this study contribute to HIV/AIDS research?
It establishes a reliable model for investigating HIV, which can aid in the development of new therapies.
What are the potential applications of hu-NSG mice?
They can be used for studying HIV therapies, understanding latency, and exploring other human diseases.
Executive Industry Relevance
The humanized NSG mouse model enables mechanistic interrogation of HIV latency and therapeutic response in a physiologically relevant system, supporting target validation and preclinical de-risking. It provides a reproducible platform for evaluating antiviral efficacy and reservoir dynamics, informing go/no-go decisions in antiviral pipeline advancement. This model bridges discovery biology with translational continuity for HIV cure research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates HIV reservoir establishment and viral rebound mechanisms post-cART withdrawal.
- Operational Value: Enables longitudinal monitoring of CD4/CD8 ratios and plasma viral load via standardized retro-orbital sampling.
- Scientific Value: Supports functional validation of latency-reversing agents and combinatorial ART regimens.
Screening & Assay Development
- Scientific Value: Generates quantifiable multi-lineage human immune engraftment for consistent baseline characterization.
- Operational Value: Delivers reproducible HIV susceptibility and cART response readouts across cohorts.
- Scientific Value: Facilitates assay-ready systems for antiviral compound screening and mechanistic profiling.
Translational & Preclinical Research
- Scientific Value: Recapitulates key biological characteristics of HIV infection and ART-mediated suppression.
- Operational Value: Provides disease-relevant system for preclinical evaluation of reservoir-targeting strategies.
- Strategic Value: Enables risk-adjusted advancement decisions based on viral load suppression and immune reconstitution metrics.
Pipeline & Workflow Integration
The hu-NSG model supports discovery biology through mechanistic de-risking of HIV targets and transitions into preclinical work for therapeutic candidate evaluation.
- Discovery Biology: Clarifies pathways of latency reservoir formation and viral persistence mechanisms.
- Screening: Delivers standardized, quantifiable outputs for antiviral efficacy and resistance profiling.
- Analytics: Enables longitudinal tracking of viral load and immune reconstitution via qRT-PCR and flow cytometry.
- Translational Research: Connects early mechanism studies to preclinical validation of reservoir reduction strategies.
- Enterprise Reuse: Serves as a reusable platform for iterative testing of HIV therapeutics across discovery and preclinical stages.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through recapitulation of HIV latency and rebound phenotypes.
- Operational Value: Standardized engraftment validation and viral load quantification ensure reproducibility across sites.
- Strategic Value: Informs capital-efficient go/no-go decisions by reducing mechanistic ambiguity in antiviral candidates.
- Portfolio Impact: Supports risk-adjusted prioritization of reservoir-targeting therapies based on preclinical efficacy signals.
Implementation Considerations
- Requires expertise in hematopoietic stem cell isolation, neonatal mouse handling, and irradiation safety protocols.
- Dependent on access to gamma irradiation sources, flow cytometry, and qRT-PCR infrastructure for engraftment and viral load analysis.
- Necessitates cross-team standardization of retro-orbital bleeding, cell processing, and ART administration timelines.
- Model adaptability limited to immunodeficient backgrounds supporting human hematopoietic engraftment.
- Engraftment variability necessitates cohort stratification based on human CD45+ cell chimerism thresholds (20–80%).
Biopharma FAQs
Why does longitudinal CD4/CD8 ratio monitoring matter for target validation?
Tracking the CD4+/CD8+ T cell ratio enables assessment of immune reconstitution and viral pathogenesis, with restoration between 1.5 and 2.5 indicating cART efficacy and informing mechanistic de-risking of latency-reversing agents.
How does irradiation-conditioned neonatal engraftment support discovery pipeline integration?
Sublethal gamma irradiation of neonatal NSG mice creates a permissive niche for human HSC engraftment, enabling multi-lineage immune system development essential for modeling HIV susceptibility and latency reservoir formation.
What quantitative plasma viral load measurements enable preclinical efficacy assessment?
Quantitative RT-PCR measurement of HIV P24 in plasma provides a sensitive, longitudinal readout of viral replication and suppression, allowing evaluation of antiviral delivery efficiency and cART-mediated viral load reduction.
Why are replication requirements critical for cross-functional collaboration in HIV model studies?
Reproducible engraftment validation (20–80% human CD45+ cells) and consistent viral susceptibility across cohorts ensure data reliability, enabling aligned interpretation between discovery, preclinical, and translational teams.
What statistical analysis capabilities are required before implementing longitudinal sampling and ART withdrawal studies?
Proficiency in longitudinal data analysis, including viral load trajectory modeling and CD4/CD8 ratio statistical comparison, is required to distinguish true viral rebound from assay variability and support go/no-go decisions.
Chapters in this video
0:04
Title
0:41
Intrahepatic Hematopoietic Stem Cell (HSC) Injection
1:59
HSC Engraftment Validation
3:48
HIV Infection Analysis and Viral Suppression and Rebound Validation
5:20
Results: Engraftment Validation and HIV Infection and Suppression Analyses
6:26
Conclusion
